Jetema Co Ltd

Jetema's capital structure shows a debt-to-equity ratio of 1.8, indicating significant leverage relative to equity. The company's liquidity position is weak, with only 4.89 billion KRW in cash and equivalents compared to 117.77 billion KRW in long-term debt. The current ratio of 0.37 suggests the company may struggle to meet short-term obligations. Despite this, the price-to-book ratio of 3.11 indicates market valuation is 3.11 times the company's book value. Profitability metrics show significant deterioration, with a return on equity of -10.09% and return on assets of -3.16%. The company reported a net loss of 6.6 billion KRW and operating loss of 1.3 billion KRW in the latest period. Gross profit of 36.84 billion KRW on 76.9 billion KRW in revenue yields a 47.9% gross margin, which is strong but insufficient to offset operating costs. Geographically, Jetema's revenue is concentrated in South Korea, with no material international operations disclosed in the financial snapshot. The company operates in a single business segment focused on pharmaceutical product development and commercialization. This concentration increases exposure to domestic regulatory and market risks. The company's growth trajectory is negative, with operating cash flow of 11.05 billion KRW but negative free cash flow of 14.83 billion KRW due to capital expenditures of 15.85 billion KRW. Analysts have assigned a mean price target of 9,000 KRW, implying 59.6% upside from the current market price of 5,650 KRW. However, the strong-buy recommendation from one analyst contrasts with no buy or hold ratings. Risk factors include liquidity constraints and negative net cash position after subtracting total debt. The company has low dilution risk with no difference between basic and diluted shares outstanding. No recent filings or transcripts were provided in the input data to assess material developments.